Policy-makers' conception of patient non-attendance fees in specialist healthcare: a qualitative document analysis.

health policy health services administration & management hospitals, public medical ethics public health qualitative research

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
24 Nov 2023
Historique:
medline: 27 11 2023
pubmed: 25 11 2023
entrez: 24 11 2023
Statut: epublish

Résumé

Patients missing their scheduled appointments in specialist healthcare without giving notice can undermine efficient care delivery. To reduce patient non-attendance and possibly compensate healthcare providers, policy-makers have noted the viability of implementing patient non-attendance fees. However, these fees may be controversial and generate public resistance. Identifying the concepts attributed to non-attendance fees is important to better understand the controversies surrounding the introduction and use of these fees. Patient non-attendance fees in specialist healthcare have been extensively debated in Norway and Denmark, two countries that are fairly similar regarding political culture, population size and healthcare system. However, although Norway has implemented a patient non-attendance fee scheme, Denmark has not. This study aimed to identify and compare how policy-makers in Norway and Denmark have conceptualised patient non-attendance fees over three decades. A qualitative document study with a multiple-case design. A theory-driven qualitative analysis of policy documents (n=55) was performed. Although patient non-attendance fees were seen as a measure to reduce non-attendance rates in both countries, the specific conceptualisation of the fees differed. The fees were understood as a monetary disincentive in Norwegian policy documents. In the Danish documents, the fees were framed as an educative measure to foster a sense of social responsibility, as well as serving as a monetary disincentive. The data suggest, however, a recent change in the Danish debate emphasising fees as a disincentive. In both countries, fees were partly justified as a means of compensating providers for the loss of income. The results demonstrate how, as a regulative policy tool, patient non-attendance fees have been conceptualised and framed differently, even in apparently similar contexts. This suggests that a more nuanced and complex understanding of why such fees are debated is needed.

Identifiants

pubmed: 38000825
pii: bmjopen-2023-077660
doi: 10.1136/bmjopen-2023-077660
pmc: PMC10679985
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e077660

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Health Policy. 2005 Oct;74(2):181-91
pubmed: 16153478
S Afr Med J. 2019 Sep 30;109(10):733-735
pubmed: 31635567
Health Policy Plan. 2021 Feb 16;35(10):1424-1431
pubmed: 33175972
JAMA. 1992 Apr 22-29;267(16):2221-6
pubmed: 1556799
Health Informatics J. 2010 Dec;16(4):246-59
pubmed: 21216805
Scand J Public Health. 2013 Nov;41(7):684-91
pubmed: 23761933
Inquiry. 2016 Jul 20;53:
pubmed: 27444505
Acta Ophthalmol (Copenh). 1994 Jun;72(3):284-9
pubmed: 7976256
Health Syst Transit. 2020 Jan;22(1):1-163
pubmed: 32863241
Tidsskr Nor Laegeforen. 2002 Jun 30;122(17):1682-5
pubmed: 12555612
J Med Ethics. 2023 Nov 23;49(12):844-849
pubmed: 36944503
Trials. 2016 Jun 13;17(1):288
pubmed: 27296439
BMJ Open. 2018 Apr 13;8(4):e019969
pubmed: 29654019
Am J Bioeth. 2012;12(2):1-10
pubmed: 22304506
Polit Psychol. 2012 Jun 1;33(3):395-418
pubmed: 23355755
Swiss Med Wkly. 2007 Dec 1;137(47-48):677-81
pubmed: 18058276
Isr J Health Policy Res. 2023 Aug 8;12(1):27
pubmed: 37550725
Health Syst Transit. 2012;14(2):i-xxii, 1-192
pubmed: 22575801
Health Policy. 2018 Apr;122(4):412-421
pubmed: 29482948
J Med Ethics. 2007 Dec;33(12):689-94
pubmed: 18055897
BMJ. 2015 Jul 05;351:h3663
pubmed: 26149174

Auteurs

Joar Røkke Fystro (JR)

Department of Health Management and Health Economics, University of Oslo, Oslo, Norway j.r.fystro@medisin.uio.no.

Eli Feiring (E)

Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH